Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
1. Ironwood reaffirms 2025 LINZESS sales guidance and raises EBITDA expectations. 2. First quarter 2025 results are expected to be reported in May.